$309.8 M

VRCA Mkt cap, 03-Jun-2020
Verrica Pharmaceuticals Net income (Q1, 2020)-9.8 M
Verrica Pharmaceuticals EBIT (Q1, 2020)-9.9 M
Verrica Pharmaceuticals Cash, 31-Mar-202054.5 M
Verrica Pharmaceuticals EV302.8 M

Verrica Pharmaceuticals Income Statement

Annual

USDFY, 2018FY, 2019

R&D expense

12.8m15.4m

General and administrative expense

9.1m14.6m

Operating expense total

21.9m30.1m

EBIT

(21.9m)(30.1m)

Interest expense

1.2m

Interest income

1.2m1.9m

Net Income

(20.6m)(28.2m)

Quarterly

USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

R&D expense

3.6m3.5m4.5m3.9m3.0m4.9m

General and administrative expense

2.5m3.7m3.5m3.6m3.5m5.0m

Operating expense total

6.1m7.2m8.0m7.5m6.5m9.9m

EBIT

(6.1m)(7.2m)(8.0m)(7.5m)(6.5m)(9.9m)

Interest expense

153.0k426.0k547.0k520.0k453.0k

Interest income

153.0k427.0k547.0k523.0k453.0k278.0k

Net Income

(6.0m)(6.7m)(7.5m)(7.0m)(6.1m)(9.8m)

Verrica Pharmaceuticals Balance Sheet

Annual

USDFY, 2018FY, 2019

Cash

10.3m9.2m

Prepaid Expenses

1.3m3.0m

Current Assets

91.2m65.0m

PP&E

255.0k2.1m

Total Assets

91.9m68.4m

Accounts Payable

922.0k1.2m

Short-term debt

130.0k

Current Liabilities

2.5m3.4m

Long-term debt

58.0k

Total Debt

188.0k

Total Liabilities

2.5m3.4m

Common Stock

3.0k3.0k

Additional Paid-in Capital

122.5m126.6m

Retained Earnings

(33.1m)(61.2m)

Total Equity

89.4m65.0m

Financial Leverage

1 x1.1 x

Quarterly

USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

103.1m38.3m24.4m19.9m10.6m54.5m

Prepaid Expenses

1.4m1.7m1.4m985.0k3.0m2.3m

Current Assets

104.6m98.7m84.7m79.7m74.0m90.6m

PP&E

112.0k114.0k1.0m1.3m1.8m2.4m

Total Assets

104.7m98.8m86.0m81.3m76.1m94.4m

Accounts Payable

1.1m1.1m1.1m1.5m1.0m1.1m

Short-term debt

13.1m

Current Liabilities

3.1m2.5m3.1m4.3m4.3m3.3m

Long-term debt

156.0k124.0k91.0k34.4m

Total Debt

156.0k124.0k91.0k47.6m

Total Liabilities

3.1m2.5m3.2m4.4m4.4m37.8m

Common Stock

3.0k3.0k3.0k3.0k3.0k3.0k

Additional Paid-in Capital

121.9m123.4m123.2m124.3m125.2m127.6m

Retained Earnings

(20.3m)(27.0m)(40.5m)(47.5m)(53.6m)(71.0m)

Total Equity

101.6m96.4m82.8m76.8m71.7m56.6m

Debt to Equity Ratio

0 x0 x

Debt to Assets Ratio

0 x0 x

Financial Leverage

1 x1 x1 x1.1 x1.1 x1.7 x

Verrica Pharmaceuticals Cash Flow

Annual

USDFY, 2018FY, 2019

Net Income

(20.6m)(28.2m)

Depreciation and Amortization

20.3k64.2k

Accounts Payable

769.0k263.0k

Cash From Operating Activities

(17.9m)(27.4m)

Purchases of PP&E

(275.0k)(682.0k)

Cash From Investing Activities

(79.9m)26.0m

Cash From Financing Activities

99.4m423.0k

Net Change in Cash

1.6m(1.0m)

Quarterly

USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(7.8m)(14.6m)(7.5m)(14.5m)(20.6m)(9.8m)

Depreciation and Amortization

5.0k10.0k11.0k22.0k38.0k14.0k

Accounts Payable

573.0k914.0k215.0k33.0k89.0k(82.0k)

Cash From Operating Activities

(5.8m)(11.0m)(6.9m)(12.0m)(19.2m)(7.9m)

Purchases of PP&E

(111.0k)(124.0k)(679.0k)(699.0k)

Cash From Investing Activities

(111.0k)(58.7m)21.1m21.3m19.3m18.3m

Cash From Financing Activities

100.4m99.4m3.0k215.0k219.0k34.9m

Net Change in Cash

94.5m29.6m14.2m9.6m329.0k45.2m

Verrica Pharmaceuticals Ratios

USDY, 2020

EV/EBIT

-30.7 x

EV/CFO

-38.3 x

Financial Leverage

1.7 x